{"id":148666,"date":"2026-08-19T13:14:26","date_gmt":"2026-08-19T13:14:26","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/148666\/"},"modified":"2026-08-19T13:14:26","modified_gmt":"2026-08-19T13:14:26","slug":"novo-begins-study-to-find-lowest-effective-dose-for-wegovy-pill-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/148666\/","title":{"rendered":"Novo begins study to find lowest effective dose for Wegovy pill"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">LONDON, Aug 19 (Reuters) &#8211; Danish drugmaker Novo Nordisk is testing lower doses of its Wegovy pill in a new late-stage study to \u200cfind the lowest dose that still helps patients lose weight, according \u200cto a U.S. government database of clinical trials.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo is under pressure after losing ground to \u200bU.S. rival Eli Lilly in the obesity drug market that analysts expect will be worth over $100 billion a year by 2030.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Its Wegovy pill, which brought in sales of 3.22 billion Danish crowns ($499.80 million) in the second quarter, is a \u200ckey focus for investors.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The new \u2060study for lower doses began on August 12 and will continue until 2028. Below are more details about the \u2060trial:  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 The trial aims to recruit 450 participants aged 18 and older who have previously struggled to lose weight through dieting.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 Patients who have a Body Mass \u200bIndex (BMI) of \u200b30 or above, or 27 or \u200babove with a weight-related health issue, \u200cwill be included in the study.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 The main goal of the study is to test whether lower doses of oral semaglutide \u2014 the active ingredient in Wegovy \u2014 help people lose more weight than a placebo over 60 weeks.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 Patients with diabetes, those with recent major weight changes, and anyone currently taking \u200cGLP-1 weight-loss medications will not be included \u200bin the study.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 The trial will also measure \u200bhow many people lose at \u200bleast 5%, 10% or 15% of their body weight, \u200cand track changes in waist size and \u200bother health measures, \u200bas well as side effects, as secondary goals.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 The database does not provide details of which dose strengths will be tested.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 The Wegovy \u200bpill is currently approved \u200cin doses of 1.5 milligrams and 4 mg, 9 mg and \u200ba higher long-term dose of 25 mg.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">($1 = 6.4426 Danish crowns)  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">(Reporting by \u200bBhanvi Satija. Editing by Mark Potter)  <\/p>\n","protected":false},"excerpt":{"rendered":"LONDON, Aug 19 (Reuters) &#8211; Danish drugmaker Novo Nordisk is testing lower doses of its Wegovy pill in&hellip;\n","protected":false},"author":2,"featured_media":148667,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[583,42778,272],"class_list":["post-148666","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-danish-crowns","tag-dose","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117122358754093522","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/148666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=148666"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/148666\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/148667"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=148666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=148666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=148666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}